A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)
Our data suggest that the CX3CR1/CX3CL1 axis is activated in CLL and may contribute to the NLC-driven growth-promoting effects of CLL cells. KAND567, which is in clinical trials in other disorders, should also be explored in CLL.
Authors
- Johan Schultz (ORCID: https://orcid.org/0000-0002-8211-1681)
- Thomas Olin
- Amineh Ghaderi
- Ali Moshfegh
- Jeanette Lundin (ORCID: https://orcid.org/0000-0002-4473-5450)
- Parviz Kokhaei (ORCID: https://orcid.org/0000-0001-6544-4209)
- Anders Österborg
- Marzia Palma (ORCID: https://orcid.org/0000-0003-4287-3179)
- Mohammad Hojjat‐Farsangi (ORCID: https://orcid.org/0000-0002-0589-5523)
- Tom A. Mulder (ORCID: https://orcid.org/0000-0002-6554-3263)
- Wen Zhong (ORCID: https://orcid.org/0009-0006-5374-147X)
- H Mellstedt
Institutions
- Karolinska University Hospital (SE)
- Arak University of Medical Sciences (IR)
- Karolinska Institutet (SE)
- Kancera (Sweden) (SE)
Publication Details
- Journal
- Cancers
- Published
- 2024-11-13
- DOI
- https://doi.org/10.3390/cancers16223821
- Citations
- 4
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.75